Timdarpacept, a SIRPα-Fc fusion protein, combined with azacitidine produced a 72.7% overall response rate in a phase II trial of 24 Chinese patients with higher-risk chronic myelomonocytic leukemia receiving treatment as first-line therapy. The report frames the results around efficacy alongside ongoing assessment of tolerability. The regimen continues a broader push to add innate immune checkpoint modulation to standard myeloid leukemia backbone therapies. Further confirmation in larger randomized settings will determine whether the response rate translates into durable disease control.